Latest Breaking News On - சோதனைகள் குழு - Page 1 : comparemela.com

UMass Medical School researchers to evaluate treatment options for early COVID-19 infection UMass Medical School Communications July 08, 2021 UMass Medical School is participating in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial, which is being led by the AIDS Clinical Trials Group (ACTG). ACTIV-2 includes both Phase II and Phase III evaluations of investigational agents for treating early COVID-19. To qualify for ACTIV-2, participants must have tested positive for SARS-CoV-2 in the outpatient setting within 10 days and started experiencing symptoms within eight days of enrolling. “The goal of ACTIV-2 is to identify treatments that can keep people who acquire COVID-19 from getting sicker and requiring hospitalization,” said Robert W. Finberg, MD, distinguished professor of medicine and lead investigator of the Medical School’s ACTIV-2 trial site. “People living in central Massachusetts who have recently been diagnosed with COVID-19 a

United statesSan diegoRobertw finbergLos angelesDavey smithJosephj eronJudith currierErics daarDavid alain wohlUniversity of californiaNational institutes of healthNational institute of allergyUmass medical schoolClinical trials groupUniversity of north carolinaLundquist institute at